Dr Oliver Sartor appointed to RAD Scientific Advisory Board
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
22 JULY 2025
DR OLIVER SARTOR APPOINTED TO RADIOPHARM SCIENTIFIC
ADVISORY BOARD
Sydney, Australia – 22 July 2025 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the
“Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology
radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the
appointment of Dr Oliver Sartor, MD to the Company’s Scientific Advisory Board (SAB).
Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate
cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical
Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo
Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and
Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of
Medicine.
Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical
School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology.
Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982,
completed internal medicine residency at Tulane, and a medical oncology fellowship at the National
Cancer Institute (NCI).
Since 1990 he has focused on prostate cancer clinical research, authoring more than 500
peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals
for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted
radioligand therapy.
“Dr Sartor brings an unparalleled depth of expertise in both clinical translation and
radiopharmaceutical therapies,” said Riccardo Canevari, Managing Director and CEO of Radiopharm
Theranostics. “We’re very honoured to welcome him to our SAB. His insight and leadership will be
invaluable as we advance our radiopharmaceutical pipeline.”
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The
company has a pipeline of distinct and highly differentiated platform technologies spanning
peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes
one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and
brain metastases. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
22 JULY 2025
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ
(Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Share your feedback
Discover